You are here

Cambridge

Then and Now: What’s Changed—and What Hasn’t—in Some Early Biopharma Hotbeds

BioSpace

Thu, 01/18/24 - 05:22 pm

GSK grabs 150K square feet of prime Boston lab space as part of RNA, viral focus

Fierce Biotech

Thu, 01/12/23 - 10:31 am

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on

Fierce Pharma

Wed, 09/21/22 - 07:53 pm

Merck cuts 170 jobs at Acceleron right on heels of $11.5B buyout

Fierce Pharma

Wed, 03/30/22 - 11:05 am

Sanofi Unites Under a Single Purpose at Cambridge Crossing

BioSpace

Mon, 03/14/22 - 10:29 am

AstraZeneca opens new advance therapeutics R&D facility in Cambridge

Biopharma Reporter

Tue, 11/23/21 - 10:03 am

With oncology spinoff done, bluebird bio moves to new digs better suited to its future

Fierce Pharma

Sun, 11/7/21 - 10:50 pm

Cambridge team says AI could diagnose dementia with one scan

Pharmaforum

Tue, 08/10/21 - 10:25 am

artificial intelligence

Bristol Myers adds on at Cambridge Crossing, settling in even further in bustling Boston-area biotech hub

Endpoints

Tue, 04/20/21 - 07:40 pm

Bristol Myers Squibb

Eisai launches first startup incubator under its genomics center for dementia

Fierce Biotech

Tue, 07/9/19 - 11:53 am

Sanofi Moving 2,700 Staffers From the Boston Suburbs to Cambridge Crossing

BioSpace

Tue, 12/18/18 - 10:30 am

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

Endpoints

Sat, 07/1/17 - 09:25 am

Flemming Ornskov

Martin Shkreli’s former biotech company Retrophin is leaving Cambridge

Bizjournals.com

Fri, 03/10/17 - 09:39 am

AstraZeneca, GSK snag a direct line to researchers at Cambridge academic hub

Fierce Biotech

Sat, 08/1/15 - 08:52 am

Cambridge Sees Pfizer Pursuit as Disrupting Science Hub

Bloomberg

Wed, 05/14/14 - 08:20 am

With new tools, Novartis targets brain disease

Boston Globe, MA

Thu, 09/19/13 - 11:14 am